Hematology

ASCO 2020

Questions discussed in this category

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

2 Answers available

Papers discussed in this category

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Related Topics in Hematology